

Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients

Véronique Hofman, Isabelle Rouquette, Elodie Long-Mira, Nicolas Piton, Emmanuel Chamorey, Simon Heeke, Jean Michel Vignaud, Clémence Yguel, Julien Mazières, Anne-Laure Lepage, et al.

▶ To cite this version:

Véronique Hofman, Isabelle Rouquette, Elodie Long-Mira, Nicolas Piton, Emmanuel Chamorey, et al.. Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients. Journal of Thoracic Oncology, 2019, 14 (7), pp.1204-1212. 10.1016/j.jtho.2019.03.024 . hal-02421514

HAL Id: hal-02421514 https://hal.umontpellier.fr/hal-02421514

Submitted on 25 Oct 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Multicenter evaluation of a novel ROS1 immunohistochemistry 1 assay (SP384) for detection of *ROS1* rearrangements in a large 2 cohort of lung adenocarcinoma patients 3 4 Véronique Hofman (1, 2, 3), Isabelle Rouquette (4), Elodie Long-Mira (1, 2, 3), 5 Nicolas Piton (5), Emmanuel Chamorey (6), Simon Heeke (2), 6 Jean Michel Vignaud (7), Clémence Yguel (7), Julien Mazières (8), Anne-Laure 7 8 Lepage (9), Frédéric Bibeau (9), Hugues Begueret (10), Sandra Lassalle (1, 2), Salomé Lalvée (1), Katia Zahaf (1), Jonathan Benzaguen (2, 11), Michel Poudenx 9 (11), Charles-Hugo Marquette (11), Jean-Christophe Sabourin (5), 10 Marius Ilié* (1, 2, 3) and Paul Hofman* (1, 2, 3)11 12 (1) Université Côte d'Azur, University Hospital Federation OncoAge, Laboratory of Clinical 13 and Experimental Pathology, Pasteur Hospital, Nice, France; 14 (2) Université Côte d'Azur, CNRS, INSERM, Institute of Research on Cancer and Ageing of 15 Nice (IRCAN), University Hospital Federation OncoAge, Nice, France; 16 (3) Université Côte d'Azur, University Hospital Federation OncoAge, Hospital-Related 17 Biobank (BB-0033-00025), Pasteur Hospital, Nice, France; 18 (4) CHU Toulouse, Department of Pathology, Toulouse, France; 19 20 (5) Charles Nicolle Hospital, Department of Pathology, Rouen, France; 21 (6) Antoine Lacassagne Comprehensive Cancer Center, Biostatistics Unit, Nice, France; 22 (7) CHU Nancy, Department of Pathology and Biobank (BB-0033-00035), Nancy, France; (8) CHU Toulouse, Larrey Hospital, Université Paul Sabatier, Toulouse, France; 23 (9) Normandie Université, Department of Pathology, Caen, France; 24 (10) CHU Bordeaux, Department of Pathology, Pessac, France; 25 (11) Université Côte d'Azur, University Hospital Federation OncoAge, Department of 26 Pulmonary Medicine and Thoracic Oncology, Nice, France 27 28 29 **Running title:** ROS1 immunohistochemistry and lung adenocarcinoma Correspondence to: Prof. Paul Hofman, Laboratory of Clinical and Experimental 30 Pathology, Pasteur Hospital, 30 Voie Romaine, BP69, 06001 Nice cedex 01, France: 31 Tel: +33 4 92 03 88 55; Fax: +33 4 92 88 50; Email: hofman.p@chu-nice.fr 32

34 Abstract

INTRODUCTION: The detection of a ROS1 rearrangement in advanced and 35 metastatic lung adenocarcinoma (LUAD) lead to a targeted treatment with tyrosine 36 kinase inhibitors, with favorable progression-free survival and overall survival of the 37 patients. Thus, it is mandatory to screen for the ROS1 rearrangement in all these 38 patients. ROS1 rearrangements can be detected using break-apart fluorescence in 39 situ hybridization (FISH), which is the "gold standard"; however, ROS1 40 immunohistochemistry (IHC) can be used as a screening test since it is widely 41 available, easy and rapid to perform, and cost-effective. 42

METHODS: We evaluated the diagnostic accuracy and inter-pathologist agreement of two anti-ROS1 IHC clones, SP384 (Ventana, Tucson, AZ) and D4D6 (Cell Signaling, Danvers, MA), in a training cohort of 51 positive *ROS1* FISH LUAD cases, and then in a large validation cohort of 714 consecutive cases of LUAD from six routine molecular pathology platforms.

RESULTS: In the two cohorts, the SP384 and D4D6 clones demonstrate variable sensitivity and specificity rates on the basis of two cutoff points ≥1+ (all % tumor cells and ≥2+ (>30% stained tumor cells). In the validation cohort, the D4D6 yielded the best accuracy for the presence of a *ROS1* rearrangement by FISH. Inter-pathologist agreement was moderate to good (ICC, 0.722–0.874) for the D4D6 clone and good to excellent (ICC, 0.830–0.956) for the SP384 clone.

54 CONCLUSIONS: ROS1 IHC is an effective screening tool for the presence of ROS1 55 rearrangements. However, users must be acutely aware of the variable diagnostic 56 performance of different anti-ROS1 antibodies prior to implementation into routine 57 clinical practice.

58

59 **Keywords:** ROS1; SP384; D4D6; immunohistochemistry; FISH; lung 60 adenocarcinoma.

62 **INTRODUCTION**

Patients with advanced and metastatic lung adenocarcinoma (LUAD) 63 harboring a ROS1 rearrangement respond effectively to crizotinib, as well as to the 64 other tyrosine kinase inhibitors that are currently used in clinical trials.¹⁻⁵ ROS1 65 screening is thus recommended in most guidelines. ROS1 rearrangement detection 66 using fluorescence in situ hybridization (FISH) is the typical approach that is 67 consistently performed to identify patients with LUAD who would be eligible for these 68 treatments. Based on its high sensitivity and specificity, this method is considered to 69 be the "gold standard" for determining ROS1 positivity.^{6, 7} However, given the low 70 incidence of *ROS1* rearrangements in lung adenocarcinoma (1% to 2%),⁶ detection 71 of ROS1 protein expression by immunohistochemistry (IHC) can be used as a 72 surrogate, cost-effective screening test that is preferable to FISH analysis for 73 screening the ROS1 status.⁸ Furthermore, the expression of the ROS1 protein, as 74 detected by IHC, may indicate a functional gene product, which is necessary for 75 effective drug targeting.⁹ Moreover, FISH testing requires high-level expertise for 76 technical and diagnostic issues, which is not widely available in all laboratories. 77 78 Finally, the turnaround time for getting the final result can sometimes delay an urgent treatment decision.¹⁰ 79

Considering these latter constraints, ROS1 IHC was recommended as a 80 frontline screening test prior to confirmatory FISH analysis in ROS1-positive cases 81 and to avoid unnecessary FISH analysis in *ROS1*-negative cases.⁸ To date, a single 82 commercially available antibody (D4D6 clone, Cell Signaling Technology, Danvers, 83 MA, USA) has been used in several studies and is currently used worldwide in 84 routine clinical practice.¹¹⁻¹³ Given the high sensitivity of IHC relative to FISH or other 85 molecular approaches, such as next generation sequencing (NGS) technologies, 97-86 98% of tumors that clearly lack ROS1 staining can be safely interpreted as negative 87 for *ROS1* rearrangement.^{6, 11-13} 88

Conversely, the interpretation of a positive ROS1 D4D6 IHC test may be challenging and can lead to false-positive results (related to a patchy pattern and weak intensity of the staining) that do not harbor an underlying *ROS1* rearrangement as detected by FISH.¹⁴⁻¹⁶ Therefore, the variability of specificity reported for the ROS1 D4D6 IHC assay requires caution and subsequent confirmation of the *ROS1* status by a validated method, irrespective of the staining intensity and the percentage

of positive tumor cells.^{15, 17} Only the confirmation of a *ROS1* rearrangement by a
molecular or cytogenetic method (e.g., FISH, NGS) can be used prior to considering
a patient with LUAD for *ROS1*-targeted therapy.^{8, 18}

In this context, the development of a new anti-ROS1 antibody (SP384 clone,
 Ventana, Tucson, AZ, USA) prompted the evaluation of its diagnostic performance to
 predict the presence of a *ROS1* rearrangement in a routine clinical setting.

101 This study aimed to investigate the correlation between two ROS1 IHC assays 102 and paired *ROS1* FISH analysis as well as inter-pathologist agreement for IHC 103 interpretation in two large-scale multicenter cohorts of LUAD cases.

104

105 **PATIENTS AND METHODS**

106 Case selection

107 The training cohort was comprised of retrospective archival formalin-fixed 108 paraffin-embedded (FFPE) tumor samples from 51 patients with stage IIIB/IV LUAD 109 and *ROS1* FISH positive. None of the *ROS1* positive cases harbored concurrent *ALK* 110 rearrangements nor *EGFR* or *BRAF* activating mutations. In *ROS1* positive patients, 111 tumor response was evaluated per RECIST 1.1 on target lesions, 3 months after the 112 initiation of crizotinib and was compared with baseline results.

In the validation cohort, 714 cases of consecutive LUAD diagnosed in the
Laboratory of Clinical and Experimental Pathology (Pasteur Hospital, Université Côte
d'Azur, Nice, France) between 2006 and 2017 were integrated in tissue microarray
(TMA) FFPE blocks. Three tissue cores of 600 μm in diameter were taken from
different tumor areas within the same FFPE block for each case.

A signed informed consent was obtained from all patients. The study was 118 approved by the local ethics committee (Human Research Ethics Committee, Nice 119 University Hospital Center/hospital-related Biobank BB-0033-00025) and was 120 performed in accordance with the guidelines of the Declaration of Helsinki. ROS1 121 FISH positive tissue samples were provided by 6 pathology laboratory centers in 122 France (University Hospitals of Bordeaux, Caen, Nancy, Nice, Rouen and Toulouse) 123 and centralized for IHC and FISH analysis in the Laboratory of Clinical and 124 Experimental Pathology (Nice, France), which is accredited by COFRAC (French 125 National Authority for Accreditation delivery, n°8-3034; www.cofrac.fr) for FISH and 126 IHC testing according to the ISO 15189 norm. 127

128 **ROS1 FISH analysis**

Tumor samples were fixed in formaldehyde 10% and paraffin, embedded at 129 each participating center before centralization. Tissue sections (4 µm thick) were 130 stained with hematoxylin eosin and the percentage of tumor cells was assessed 131 independently by three senior thoracic pathologists (VH, MI, PH). Briefly, FISH 132 analysis was conducted using the Abbott Molecular FISH probe (Abbott Molecular 133 Inc., Des Plaines, IL, USA), LSI ROS1 (Tel) SpectrumOrange Probe and LS1 ROS1 134 (Cen) SpectrumGreen Probe. Additionally, some tumors were assessed for ROS1 135 rearrangement using the ZytoLight SPEC ROS1 Dual Colour Break Apart Probe 136 (ZytoVision, Bremerhaven, Germany). FISH was performed according to the 137 manufacturer's recommendations. Interphase signals were manually counted in at 138 least 100 tumor nuclei per case using an epi-fluorescence microscope (Eclipse 80i, 139 140 Nikon, Champigny-sur-Marne, France) supported in parallel by the PathScan® Viewer software (Excilone, Elancourt, France). 141

A positive case was defined if more than 15% of tumor cells in more than 100 tumor cells demonstrated a split signal at least 2 signal distances apart or an isolated centromeric 3' (green signal) pattern.

145

ROS1 IHC analysis

ROS1 IHC analysis was performed using the D4D6 clone (Cell Signaling 146 Technology, Danvers, MA, USA; CC1 buffer for 64 min, 1:50 dilution for 32 min, 147 ultraView Universal DAB Detection Kit, Ventana, Tucson, AZ, USA) and the SP384 148 clone (Ventana, Tucson, AZ, USA; CC1 buffer for 64 min, 1:50 dilution for 16 min, 149 OptiView DAB IHC Detection Kit, Ventana) and processed on the Ultra Benchmark 150 autostainer (Ventana) according to the manufacturer's recommendations. 151 Immunostainings were interpreted independently by three senior lung pathologists 152 (VH, MI, PH), blinded to FISH results, for the following criteria: signal intensity (0; no 153 staining, 1+; weak, 2+; moderate; and 3+; strong) and percentage of stained cells, 154 topography and characteristics of the signal (cytoplasmic – diffuse or focal and/or 155 granular; cytoplasmic and membranous; membranous). Results were quantified by 156 multiplying the percentage of ROS1 positive tumor cells by the intensity (H-score, 157 range, 0-300). For each case included on the TMA FFPE blocks, the mean H-score 158 of the three cores was recorded. Non-specific staining of macrophages and type II 159

pneumocytes was disregarded. ROS1 negative and positive controls were put on
 each IHC slide (HCL0024, HistoCyte Laboratories Ltd, Newcastle University, UK).

162

Statistical analysis

Statistical analyses assessing agreement between the D4D6 and SP384 163 antibodies with the ROS1 FISH analysis (gold standard) were performed on 164 dichotomized variables using two positivity cutoff points: IHC ROS1 positive (intensity 165 \geq 1+, any percentage of tumor cells) and IHC ROS1 strongly positive (intensity \geq 2+, 166 >30% tumor cells), as recently described.^{17, 19} Sensitivity, specificity, positive 167 predictive value (PPV), negative predictive value (NPV), and accuracy were 168 calculated for the comparison between the dichotomized results using each of the 169 two antibodies relative to the FISH results. The Spearman's rank correlation test (*rho*) 170 was used for a correlation analysis between the H-scores as continuous variables of 171 172 each clone. Intra-class correlation coefficients were calculated for the comparison of H-scores as continuous variables from each of the ROS1 clones, and k scores were 173 calculated for dichotomized results based on two positivity cutoff points, as described 174 above, to assess the inter-pathologist agreement for each of the clone. The paired 175 Student's t-test was used to assess the correlation between the ROS1 IHC status 176 and RECIST 1.1. All statistical analyses were carried out using R software (version 177 3.2.2, R Core Team, Vienna, Austria). Any *P*-value <0.05 was assumed to indicate a 178 statistically significant difference. 179

180

181 **RESULTS**

182 Training cohort

In a clinically selected cohort enriched for tumors with FISH-identified ROS1 183 rearrangements, the frequency of split or isolated centromeric signals averaged 64% 184 and ranged from 15% to 100%. IHC SP384 showed strong 3+ expression in 40/51 185 (78%), 2+ moderate in 10/51 (20%) and 1+ weak in 1/51 (2%) of cases (Table 1, 186 Figure 1). IHC D4D6 showed a wider range of intensity in 15/51 (30%) with 3+ 187 staining, 16/51 (31%) with 2+ staining and 20/51 (39%) with 1+ staining (Table 1, 188 Figure 1). Inter-pathologist agreement was high in interpreting both ROS1 IHC 189 clones (Supplementary Table S1). 190

191 On the basis of the \geq 1+ expression cutoff, both ROS1 IHC clones are 100% 192 sensitive, whereas if \geq 2+ tumors are considered positive, the SP384 clone is 98% sensitive and D4D6 is only 61% sensitive for the detection of a ROS1 rearrangement
by FISH (**Table 1**).

H-scores ranged from 5 to 300 and from 50 to 300 when using the D4D6 and
SP384 clones, respectively. However, the Spearman's rank correlation was not linear
(*rho*=0.508; 95% Cl, 0.19–0.72) between the two clones (**Figure 1**, **Supplementary Figure S1**).

199 Neither the intensity nor the percentage of ROS1 protein expression detected 200 with both SP384 and D4D6 antibodies correlated with the percentage of ROS1 split 201 signals by FISH (**Supplementary Figure S2**).

In most of the cases analyzed with the SP384 clone, a diffuse cytoplasmic 202 203 staining was observed with or without membranous staining (Figure 2). Less frequently, a granular cytoplasmic or a membranous staining alone was noted 204 205 (Figure 2). Corresponding D4D6 IHC staining was weaker and in some cases the percentage of positive tumor cells was lower than those noted in the corresponding 206 207 tumors stained with the SP384 clone (Figure 1, Supplementary Figure S1). ROS1 protein expression was also seen with both D4D6 and SP384 antibodies in non-208 209 neoplastic alveolar epithelium at the tumor periphery, in sub-pleural pneumocytes or in areas of type II pneumocyte hyperplasia and bronchiolar metaplasia. However, the 210 expression in this epithelium was weak in intensity in most cases. 211

In this retrospective study, at the time of clinical care, the vast majority of 212 ROS1 positive patients, as confirmed by FISH, were treated with crizotinib in the 213 second and third line settings. After 3 months, 18% of patients had a complete 214 response, 19% demonstrated a partial response, 19% had stable disease, and 44% 215 had progressive disease (Supplementary Figure S3). In total, 56% of patients had 216 disease control after 3 months on crizotinib. However, no significant difference 217 existed between the two IHC clones (Supplementary Figure S3) nor between the % 218 of rearranged tumor cells by FISH and the response by RECIST (t-test, P-219 value=0.306). In order to identify putative resistance mechanisms²⁰, an NGS analysis 220 (Ion AmpliSeg Cancer Hotspot Panel, ThermoFisher Scientific, San Francisco, CA, 221 USA) was performed in two patients with progressive disease and available tumor 222 material. In one patient, we found a mutation in the gene encoding for β -catenin 223 (CTNNB1 p.S45F, VAF 43%). The NGS analysis detected no copy-number 224

variations. Moreover, these cases had no *ROS1* copy-number gain, as determined by
 FISH.²⁰

227 Validation cohort

A total of 714 cases of LUAD with an unknown *ROS1* rearrangement status were screened on TMA blocks using paired a ROS1 IHC and FISH assay. *ROS1* rearrangements were detected in this screening cohort by FISH at a rate of 9 of 714 cases (1.3%).

On the basis of the \geq 1+ expression cutoff, both ROS1 IHC clones are 100% sensitive for the presence of a ROS1 translocation detected by FISH, while the D4D6 clone was deemed more specific and accurate (**Table 1, Figure 3**). Conversely, on the basis of the \geq 2+ expression cutoff, the SP384 clone was more sensitive than the D4D6 clone, while the D4D6 was more specific and accurate than SP384 (**Table 1, Figure 3**).

Inter-pathologist agreement ranged from moderate to good (ICC, 0.722–0.874)
 in interpreting the D4D6 IHC assay and from good to excellent (ICC, 0.830–0.956) for
 the SP384 IHC assay (Supplementary Table S1).

241

242

243 **DISCUSSION**

This is the first study to assess the diagnostic performance of a newly developed anti-ROS1 antibody (SP384 clone) by comparison to two diagnostic ROS1 assays that are validated for a clinical setting (e.g., D4D6 IHC and ROS1 break-apart FISH assays) in two large-scale multicenter cohorts of LUAD cases.

We considered two cutoffs for positivity and showed that none of the ROS1 248 IHC assays demonstrated 100% accuracy in detection of ROS1 rearrangements as 249 identified by FISH. In the validation cohort of ROS1-positive LUAD cases, while these 250 two clones demonstrate similar sensitivity around the $\geq 1 + \text{cutoff}$, the sensitivity rate 251 dropped at 61% for the D4D6 clone when the \geq 2+ cutoff was applied. In addition, the 252 intensity and the percentage of stained tumor cells were higher when using the 253 SP384 clone than with the D4D6 clone. Inter-reader agreement varied from moderate 254 to good when interpreting the D4D6 assay, while it was deemed good to excellent for 255 the SP384 clone, as recently reported.¹⁹ Most of the cases analyzed with the SP384 256 257 clone showed diffuse cytoplasmic staining, with or without membranous labeling.

It is noteworthy that the percentage and the intensity of SP384 and D4D6 IHC
did not correlate with the percentage of *ROS1* FISH split signals, as had previously
been reported.¹² No significant difference was noted between the different ROS1 IHC
assays and the RECIST 1.1 subgroups in patients treated with crizotinib.

In our screening cohort, which was drawn from a clinical molecular diagnostics 262 practice, ROS1 rearrangement was detected in 1.3% of tumors, compared to 1–2% 263 of unselected LUAD cases, as previously reported.⁶ Around the \geq 1+ cutoff, sensitivity 264 was similar for both IHC assays; however, the specificity of the D4D6 clone (97.87%) 265 was higher than that of the SP384 clone (87.38%). We also explored the recently 266 described \geq 2+ cutoff in >30% tumor cells.^{17, 19} Whereas the sensitivity of the D4D6 267 clone declined to 66.67% under these criteria, and was 88.89% for the SP384 268 antibody, the specificity was still higher for the D4D6 assay (99.57%) than the SP384 269 clone (91.06%). 270

The average H-score of the SP384 clone was higher that the D4D6 antibody, which led to easier interpretation. However, if an algorithm for *ROS1* testing that is similar to that established for *ALK* status testing were used and if the \geq 1+ cutoff were to be used for both IHC clones, this could lead to an increase of nearly 10% in unnecessary FISH testing based on screening with the SP384 clone. Moreover, in our study, the \geq 2+ cutoff in >30% tumor cells did not improve the sensitivity and specificity rates of either IHC assay.

When newly developed diagnostic assays for the detection of rare events such as *ROS1* rearrangements are considered for implementation in a routine clinical setting, our findings highlight the importance of their evaluation in large-scale cohorts, and the necessity of both positive and negative cases. As accurate detection of *ROS1* rearrangements in clinical tumor samples is mandatory for optimal targeted treatment, investigation of new testing modalities should not be limited to positive samples only.¹⁸

Previous studies reported ROS1 D4D6 IHC as being highly sensitive, but less 285 specific compared with FISH for the detection of ROS1 rearrangements. ROS1 286 D4D6-positive tumors, especially when the tumor is stained with moderate to strong 287 intensity or a diffuse pattern, are recommended to undergo FISH to confirm the 288 presence of ROS1 rearrangement.¹²⁻¹⁴ Besides the assessment of the ROS1 289 290 rearrangement status, it is mandatory to systematically detect other genomic alterations in advanced and metastatic lung adenocarcinoma. This can be performed 291 292 by molecular biology (e.g., *EGFR* mutation) and by molecular and/or IHC approaches (e.g., BRAFV600 mutation, ALK rearrangement). Moreover, PD-L1 IHC is now 293 required in this population. Additionally, the evaluation of other genomic alterations 294 (e.g., *RET* rearrangement, *MET* mutations, *HER2* mutations, *NTRK* rearrangement) 295 can be required if the tumors are EGFR, ALK, ROS1 and BRAF wild-type and with 296 less than 50% of PD-L1 positive tumor cells. Moreover, recent clinical trials for 297 immunotherapy associated with the assessment of the tumor mutation burden (TMB) 298 have indicated some promising results for the systemic use of this predictive 299 biomarker in the near future.^{21, 22} In this context, one challenge is to be able to 300 perform these analyses on smaller tissue biopsies and/or samples with low 301 proportions of tumor cells (less than 20%). Considering that a minimum number of 302 tissue sections are required for the diagnosis of NSCLC, it is critical to conserve 303 tissue as much as possible for ancillary analyses (different predictive IHC, targeted 304 sequencing analyses or NGS panels - potentially including TMB assessment). In this 305 context, it is of interest to economize and only use tissue sections for ROS1 FISH 306 analysis in IHC positive cases. More importantly, the feasibility of using ROS1 IHC for 307 ROS1 status assessment has many advantages in comparison with the ROS1 FISH. 308

309 IHC is available in all pathology laboratories and can easily be conducted. The 310 turnaround time to get the results is much shorter than the FISH approach. IHC is a 311 cost-effective technology. Finally, shipment and archiving of stained slides can be 312 done at room temperature.

Different testing approaches, such as DNA-based hybrid capture library 313 preparation followed by NGS, RNA-based anchored multiplex polymerase chain 314 reaction library preparation followed by NGS or nCounter technologies could allow 315 the simultaneous detection of gene rearrangements such ALK, ROS1, RET, or 316 *NTRK*.^{18, 23, 24} Thus, it might be questionable whether the development of IHC assays 317 for the detection of these alterations should continue, in particular for ROS1 318 rearrangement. However, some difficulties can be encountered for the NGS 319 approach in comparison with the IHC method in a clinical setting.²⁵ Depending on the 320 321 quantity and quality of nucleic acids present in the FFPE tissue biopsy, NGS can give false negative results, in particular in small specimens and/or when a low percentage 322 323 of tumor cells are present. Moreover, the technology is not available in all laboratories and requires specific and high-level expertise. The time lag for results is 324 325 also much longer than for IHC testing. Finally, the accreditation is certainly easier to obtain for an IHC test than for a test developed on an NGS platform. 326

Assuming that the implementation of the SP384 IHC assay in the testing 327 algorithm of advanced and metastatic LUAD patients can be considered, following 328 the results showed in the present work and probably other forthcoming studies, 329 independent validation studies need to be performed. In addition, it will be of interest 330 to further assess the performance of the SP384 clone on cytology samples such as 331 cellblocks.^{26, 27} Finally, as a perspective, the ROS1 IHC assay could be a good 332 candidate to be associated with other "predictive" antibodies such as the anti-ALK, 333 anti-BRAFV600E and anti-PD-L1 in a chromogenic multiplex IHC assay for small 334 tissue biopsies.²⁸ 335

In conclusion, ROS1 IHC testing is an effective screening tool for the presence of *ROS1* rearrangements. However, users must be aware of the variable diagnostic performance of different commercialized anti-ROS1 antibodies before incorporation into the diagnostic molecular pathology workup of LUAD cases.

340

342 Funding

This work was supported by a grant from the Canceropôle PACA and the "Conseil Départemental des Alpes-Maritimes". SH is a research fellow of the Labex Program Signalife (Université Côte d'Azur).

346

347 **Conflict of interests:**

- I.R. has received honoraria from AstraZeneca, MSD, Bristol-Myers Squibb,
 Boehringer-Ingelheim, Roche and Takeda.
- 350 J.M has received research grant and honoraria from Roche, AstraZeneca and Bristol-
- Myers Squibb, and honoraria from Boehringer-Ingelheim, MSD, PharmaMar, Pfizer,Takeda.
- F.B. has received honoraria from Bristol-Myers Squibb, MSD, Amgen, Merck & Co.,
- Sanofi, Haliodx and AstraZeneca, and grants and travel expenses from Bristol-Myers
 Squibb and MSD.
- J-C.S. has received honoraria from Amgen, Roche, Pfizer, MSD, Bristol-Myers Squibb, Merck & Co., AstraZeneca and Boehringer-Ingelheim.
- M.I. has received honoraria and travel grants from AstraZeneca, Bristol-Myers Squibb, Roche, Boehringer-Ingelheim and Merck & Co.
- P.H. has received honoraria and travel grants from AstraZeneca, Roche, BristolMyers Squibb, Novartis, MSD, Qiagen, Thermofisher, Biocartis, and Merck & Co.
- 362
- 363 The remaining authors have declared no conflict of interests.
- 364
- 365
- 366
- 367
- 368
- 369
- 370
- 371
- 372
- 272
- 373
- 374
- 375

- 376 Legend to Figures
- 377

Figure 1. Representative images of ROS1 IHC using the D4D6 and the SP384 antibodies in the training cohort. (A) Strong diffuse staining with the SP384 antibody, and (B) weak to moderate diffuse staining with the D4D6 antibody in the same case as in (A). (C) Weak to moderate diffuse staining with the SP384 antibody, and (D) weak focal staining with the D4D6 antibody in the same case as in (C). A *ROS1* rearrangement was identified in both cases (A-B, and C-D) by FISH. (Scale bars are shown on the figures).

- 385
- 386 Figure 2. Representative immunostaining localization in tumor cells using the
- SP384 antibody. (A) Diffuse cytoplasmic. (B) Membranous and cytoplasmic. (C)
 Membranous. (D) Cytoplasmic granular. Scale bars are shown on the figures.
- 389

390 Figure 3. Representative comparative images between the ROS1 IHC using the

- D4D6 and the SP384 antibodies and the ROS1 FISH analysis in the validation
 cohort.
- (A) Strong diffuse (3+) staining with the D4D6 and SP384 antibodies in a LUAD case
 positive by ROS1 FISH.
- (B) Weak diffuse staining (1+) with the D4D6 antibody but strong staining (3+) with
 the SP384 clone in a LUAD case positive by ROS1 FISH.
- (C) Weak diffuse staining (1+) with the D4D6 antibody and moderate staining (2+)
 with the SP384 clone in a LUAD case positive by ROS1 FISH.
- (D) Lack of staining with both D4D6 and SP384 clones in a LUAD negative by ROS1FISH.
- (E) No staining with the D4D6 clone in a LUAD case moderately stained (2+) with
 SP384 clone and positive by ROS1 FISH.
- (F) No staining with the D4D6 clone in a LUAD case strongly stained (3+) with the
 SP384 clone but revealed negative by ROS1 FISH.
- Red circles; positive tumor cells by FISH; green circles, negative tumors cells byROS1 FISH.
- 407
- 408
- 409

- 410 Legend to Supplementary Figures

412 Supplementary Figure S1. Distribution plot of H-scores for each anti-ROS1413 antibody.

Supplementary Figure S2. Correlation analysis between the H-scores of (A) D4D6
or (B) SP384 clones and the percentage of tumor cells harboring *ROS1*rearrangement by FISH. *Note: the X-axis in (A) is manually set to have a maximum of*300 to match with SP384.

Supplementary Figure S3. Correlation analysis between response assessments by
RECIST 1.1 after 3 months under crizotinib and the IHC status by D4D6 (paired
Student's t-test; P=0.002) and SP384 (paired Student's t-test; P=0.006) clones.
Abbreviations: Progressive Disease (PD), Stable Disease (SD), Partial Response
(PR), Complete Response (CR).

Training cohort	SP384 IHC				D4D6 IHC			
FISH ROS1	Strong 3+	Moderate 2+	Weak 1+	Negative 0	Strong 3+	Moderate 2+	Weak 1+	Negative 0
Positive n = 51	40 (78%)	10 (20%)	1 (2%)	0 (0%)	15 (30%)	16 (31%)	20 (39%)	0 (0%)
Sensitivity Cutoff ≥1+ Cutoff ≥2+	100% (95% CI, 93.02%–100%) 98.04% (95% CI, 89.55%–99.95%				100% (95% CI, 93.02%–100%) 60.78% (95% CI, 46.11%–74.16%)			
Validation cohort	SP384 IHC				D4D6 IHC			
FISH ROS1								
Positive n = 9 (1.3%)	6 (67%)	2 (22%)	1 (11%)	0 (0%)	3 (33%)	3 (33%)	3 (33%)	0 (0%)
Negative n = 705 (98.7%)	0 (0%)	63 (9%)	26 (4%)	616 (87%)	0 (0%)	3 (1%)	12 (2%)	690 (97%)
Cutoff ≥1+								
Sensitivity	100% (95% CI, 66.37%–100%)				100% (95% CI, 66.37%–100.00%)			
Specificity	87.38% (95% Cl, 84.70%–89.74%				97.87% (95% Cl, 96.51–98.80%)			
PPV	9.18% (95% CI, 7.69%–10.94%)				37.50% (95% Cl, 26.67%–49.75%)			
NPV	100%				100%			
Accuracy	87.54% (95% Cl, 84.89%–89.87%)				97.90% (95% Cl, 96.56%–98.82%)			
Cutoff ≥2+								
Sensitivity	88.89% (95% Cl, 51.75%–99.72%)				66.67% (95% Cl, 29.93%–92.51%)			
Specificity	91.06% (95% Cl, 88.71%–93.06%)				99.57% (95% Cl, 98.76%–99.91%)			
PPV	11.27% (95% Cl, 8.37%–15.01%)				66.67% (95% Cl, 37.12%–87.14%)			
NPV	99.84% (95% Cl, 99.02%–99.98%)				99.57% (95% Cl, 98.93%–99.83%)			
Accuracy	91.04% (95% CI, 88.70%–93.03%)				99.16% (95% Cl, 98.18%–99.69%)			
Abbreviations: FISH, F	luorescence in situ	hybridization; NPV, Ne	egative Predictive Val	ue; PPV, Positive Pre	edictive Value.			

 Table 1. Comparative performance analyses between ROS1 FISH and SP384 and D4D6 IHC clones.

References

1. Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. *Lancet Oncol* 2017;18:1590-1599.

2. Li Z, Shen L, Ding D, et al. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer. *J Thorac Oncol* 2018;13:987-995.

3. Sgambato A, Casaluce F, Maione P, et al. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. *Expert Rev Anticancer Ther* 2018;18:71-80.

4. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;371:1963-1971.

5. Mazieres J, Zalcman G, Crino L, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. *J Clin Oncol* 2015;33:992-999.

6. Bubendorf L, Buttner R, Al-Dayel F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. *Virchows Arch* 2016;469:489-503.

7. Jurmeister P, Lenze D, Berg E, et al. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. *Lung Cancer* 2015;87:122-129.

8. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. *J Thorac Oncol* 2018;13:323-358.

9. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. *Clin Cancer Res* 2013;19:4040-4045.

10. Ilie M, Hofman P. The potential value of immunohistochemistry as a screening tool for oncogenic targets of personalized lung cancer therapy. *J Oncopathol* 2013;1:1.

11. Yoshida A, Tsuta K, Wakai S, et al. Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. *Mod Pathol* 2014;27:711-720.

12. Sholl LM, Sun H, Butaney M, et al. ROS1 immunohistochemistry for detection of ROS1-rearranged lung adenocarcinomas. *Am J Surg Pathol* 2013;37:1441-1449.

13. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. *Lung Cancer* 2014;83:168-173.

14. Cha YJ, Lee JS, Kim HR, et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. *PLoS One* 2014;9:e103333.

15. Luk PP, Selinger CI, Mahar A, et al. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization. *Arch Pathol Lab Med* 2018.

16. Rogers TM, Russell PA, Wright G, et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. *J Thorac Oncol* 2015;10:611-618.

17. Selinger CI, Li BT, Pavlakis N, et al. Screening for ROS1 gene rearrangements in non-small-cell lung cancers using immunohistochemistry with FISH confirmation is an effective method to identify this rare target. *Histopathology* 2017;70:402-411.

18. Davies KD, Le AT, Sheren J, et al. Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. *J Thorac Oncol* 2018;13:1474-1482.

19. Hanlon Newell A, Liu W, Bubendorf L, et al. MA26.07 ROS1 (SP384) Immunohistochemistry Inter-Reader Precision Between 12 Pathologists. *J Thorac Oncol* 2018;13:S452-S453.

20. McCoach CE, Le AT, Gowan K, et al. Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer. *Clin Cancer Res* 2018;24:3334-3347.

21. Heeke S, Hofman P. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not? *Transl Lung Cancer Res* 2018;7:631-638.

22. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus lpilimumab in Lung Cancer with a High Tumor Mutational Burden. *N Engl J Med* 2018;378:2093-2104.

23. Rossi G, Jocolle G, Conti A, et al. Detection of ROS1 rearrangement in nonsmall cell lung cancer: current and future perspectives. *Lung Cancer (Auckl)* 2017;8:45-55.

24. Reguart N, Teixido C, Gimenez-Capitan A, et al. Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. *Clin Chem* 2017;63:751-760.

25. Hofman V, Lassalle S, Bence C, et al. Any Place for Immunohistochemistry within the Predictive Biomarkers of Treatment in Lung Cancer Patients? *Cancers (Basel)* 2018;10.

26. Lozano MD, Echeveste JI, Abengozar M, et al. Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less. *Arch Pathol Lab Med* 2018;142:291-298.

27. Vlajnic T, Savic S, Barascud A, et al. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry. *Cancer Cytopathol* 2018;126:421-429.

28. Ilie M, Beaulande M, Hamila M, et al. Automated chromogenic multiplexed immunohistochemistry assay for diagnosis and predictive biomarker testing in non-small cell lung cancer. *Lung Cancer* 2018;124:90-94.

Figure 1




Figure 2

